drugset / Trial / NCT04731467
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
RandomizedSequentialOpen-labelTreatment
Summary
This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C \& D) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV will be administered subsequent to CM24 and nivolumab. CM24, nivolumab and gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV are administered intravenously.
Timeline
- Start
- 2021-03-19
- Primary completion
- 2024-09-30
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM-24 | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | LV | Unknown | — | Intravenous |
| Background | Nab-paclitaxel | Small molecule | — | Intravenous |
| Background | fluorouracil | Small molecule | — | Intravenous |
| Background | nal-IRI | Unknown | — | Intravenous |